Drugs in Dev.
Endocrinology
Phase I
Italy 
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : NP-500
Therapeutic Area : Endocrinology
Study Phase : Phase I
Sponsor : Atlas Sciences
Deal Size : $1.5 million
Deal Type : Licensing Agreement
Details : Under the the license, Jaguar has to initiate Phase 2 study of NP-500 under an investigational new drug application with the U.S. FDA or an IND-equivalent dossier within six months of April 15, 2020.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
April 16, 2020
Lead Product(s) : NP-500
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Sponsor : Atlas Sciences
Deal Size : $1.5 million
Deal Type : Licensing Agreement
